Loading stock data…
Dyne Therapeutics (DYN)
$21.26+0.32 (+1.53%)
Market ClosedLast close Jun 29
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dyne Therapeutics, Inc. in the Healthcare sector is trading at $21.26 with a market capitalization of $3.0B. Wall Street consensus targets $38.25 (16 analysts), implying a +79.9% move over the next 12 months. The stock is currently 15% below its 52-week high of $25.00, remaining 18.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +79.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$125.28M↓ | -$116.13M↓ | -$113.89M↑ | -$115.79M↑ | -$122.37M |
| Net Income | -$120.85M↓ | -$111.95M↓ | -$108.04M↑ | -$110.86M↑ | -$115.36M |
Peer Comparison
JNJUNHPFE
Fundamentals
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, includi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.22%
Volume
Today's trading volume
2.14M
Recent News
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 best AI driven biotech stocks to invest in. On June 3, enrollment for the Phase 1/2 ACHIEVE trial’s registrational expansion cohort, which evaluates z-basivarsen (DYNE-101) in individuals with myotonic dystrophy type 1 (DM1), has concluded, according to a statement from Dyne Therapeutics Inc. (NASDAQ:DYN). The business […]
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 26, Dyne Therapeutics Inc. (NASDAQ:DYN) reached a major regulatory milestone by submitting its official Biologics License Application to the FDA for its new Duchenne muscular dystrophy treatment, z-rostudirsen. The company is seeking a Priority Review […]
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone
Dyne Therapeutics (DYN) has fully enrolled the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for z-basivarsen in myotonic dystrophy type 1, a key step toward potential U.S. Accelerated Approval. See our latest analysis for Dyne Therapeutics. The latest clinical milestones appear to be feeding into improving sentiment, with Dyne’s share price at US$18.41 and a 90 day share price return of 23.89%. The 1 year total shareholder return of 31.59% and 3 year total shareholder return...
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.